Conference | Friends of Cancer Research

You are here


Designing the Future of Cell Therapies

Friends of Cancer Research and the Parker Institute for Cancer Immunotherapy are pleased to convene a public meeting bringing together leaders in cancer drug development, federal health and regulatory agencies, academic research, the private sector, and patient advocates to address key concepts and issues in cellular therapy development.

Biopharma Congress IV


November 14, 2018

The Ritz-Carlton, Washington D.C.

1150 22nd Street, NW



Biopharma Congress III

Thank you to all that attended. To access a full recap of this archived meeting, please Click HERE.

Cancer Moonshot: One Year Later


June 27, 2017, 10am – 4:30pm
JW Marriott
Washington, DC

10:00am – 10:15am  Welcome 

  • Kim Thiboldeaux, CEO, Cancer Support Community

10:15am – 10:30am  Patient Perspective

Friends of Cancer Research Annual Meeting 2017

The Ritz-Carlton, 1150 22nd St NW

Washington, DC 20037


Biopharma Congress II: Election Impact On Biopharma in 2017

Election Impact On Biopharma in 2017

November 4, 2016

Ritz-Carlton Washington, DC

1150 22nd Street, NW


Alliance for Regenerative Medicine's Immuno-Oncology Clinical & Patient Education Roundtable

On May 24, 2016, Friends cohosted the 2016 Immuno-Oncology Clinical and Patient Roundtable with the Alliance for Regenerative Medicine. This roundtable consisted of experts in the field of immuno-oncology and regulatory health policy, as well as patients. Panelists came from diverse backgrounds, including academia, industry, and government. The event aimed to educate and inform major stakeholders in cancer research about the most recent scientific breakthroughs and the challenges faced by researchers and policymakers in the field of immuno-oncology.


Prevision Policy and Friends of Cancer Research Biopharma Congress

For the past five years, Prevision Policy has hosted a high-level conference focused on FDA and CMS policy issues. This year, Friends joined as co-hosts for the 2015 Biopharma Congress.